Skip to main content

How Dr. Matthew Cooper leverages dd-cfDNA to replace protocol biopsies for surveillance, in-line with ASTS recommended use

In this episode of our Inside the ProActive Study Podcast, Dr. Matthew Cooper shares his insights on:

• Utilizing cfDNA alongside DSA and biopsies before implementing his dd-cfDNA surveillance protocol.

• Reducing biopsy usage by 75% and being a “better consumer of biopsies” through dd-cfDNA surveillance.

• Aligning his experience with the ProActive Interim Data finding of dd-cfDNA as “a leading indicator that something is wrong”.

• His actions when observing increases in dd-cfDNA levels prior to confirming rejection.

• Why the American Society of Transplant Surgeon recommends serial dd-cfDNA measurements in kidney transplant recipients.